PLx Pharma Inc. Reports Second Quarter 2017 Results

Published: Aug 11, 2017

HOUSTON, Aug. 10, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today financial results for the three- and six-month periods ended June 30, 2017.

Highlights of and subsequent to the second quarter of 2017 include:

Back to news